Literature DB >> 22209421

HFE C282Y homozygosity is associated with an increased risk of total hip replacement for osteoarthritis.

Yuanyuan Wang1, Lyle C Gurrin, Anita E Wluka, Nadine A Bertalli, Nicholas J Osborne, Martin B Delatycki, Graham G Giles, Dallas R English, John L Hopper, Julie A Simpson, Stephen Graves, Katrina J Allen, Flavia M Cicuttini.   

Abstract

OBJECTIVE: The evidence for an association between mutations in the HFE (hemochromatosis) gene and the risk of hip or knee osteoarthritis is inconsistent. Total joint replacement is considered a surrogate measure for symptomatic end-stage osteoarthritis. We examined the relationship between HFE gene mutations and risk of total hip and knee replacement using a prospective cohort study.
METHODS: The Melbourne Collaborative Cohort Study recruited participants between 1990 and 1994. Participants born in Australia, New Zealand, the United Kingdom, or Ireland (n = 27,848) were genotyped for the HFE C282Y mutation. Total hip and knee replacements for osteoarthritis during 2001 to 2009 were ascertained from the Australian Orthopaedic Association National Joint Replacement Registry. Hazard ratios (HR)/odds ratios (OR) and confidence intervals (CI) were obtained from Cox regression or logistic regression.
RESULTS: Compared with those with no C282Y mutation, C282Y homozygotes had an increased risk of single total hip replacement (HR 1.94, 95% CI 1.04-3.62) and bilateral total hip replacement (OR 5.86, 95% CI 2.36-14.57) for osteoarthritis, adjusting for age, sex, body mass index, and educational level. Only 3 C282Y homozygotes had single total knee replacement; the HR was 0.51 (95% CI 0.16-1.57). C282Y/H63D compound heterozygosity was not related to the risk of total hip or knee replacement.
CONCLUSIONS: HFE C282Y homozygosity was associated with an increased risk of both single and bilateral total hip replacement for osteoarthritis. Crown
Copyright © 2012. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209421     DOI: 10.1016/j.semarthrit.2011.11.003

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  6 in total

Review 1.  HFE-related hemochromatosis: an update for the rheumatologist.

Authors:  Emma Husar-Memmer; Andreas Stadlmayr; Christian Datz; Jochen Zwerina
Journal:  Curr Rheumatol Rep       Date:  2014-01       Impact factor: 4.592

2.  Effect of C282Y genotype on self-reported musculoskeletal complications in hereditary hemochromatosis.

Authors:  António Camacho; Thomas Funck-Brentano; Márcio Simão; Leonor Cancela; Sébastien Ottaviani; Martine Cohen-Solal; Pascal Richette
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

3.  Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents.

Authors:  Etheresia Pretorius; Janette Bester; Natasha Vermeulen; Boguslaw Lipinski; George S Gericke; Douglas B Kell
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

4.  Bone and joint complications in patients with hereditary hemochromatosis: a cross-sectional study of 93 patients.

Authors:  Chi-Duc Nguyen; Vincent Morel; Adeline Pierache; Georges Lion; Bernard Cortet; René-Marc Flipo; Valérie Canva-Delcambre; Julien Paccou
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-07-16       Impact factor: 5.346

5.  HFE hemochromatosis screening in patients with severe hip osteoarthritis: A prospective cross-sectional study.

Authors:  Bastian Oppl; Emma Husar-Memmer; Svea Pfefferkorn; Martha Blank; Peter Zenz; Eva Gollob; Christian Wurnig; Alfred Engel; Andreas Stadlmayr; Gökhan Uyanik; Wolfgang Brozek; Klaus Klaushofer; Jochen Zwerina; Christian Datz
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

6.  Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank.

Authors:  Luke C Pilling; Jone Tamosauskaite; Garan Jones; Andrew R Wood; Lindsay Jones; Chai-Ling Kuo; George A Kuchel; Luigi Ferrucci; David Melzer
Journal:  BMJ       Date:  2019-01-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.